UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 86.

von Moos, S; Cippà, P E; Wüthrich, R P; Mueller, T F (2016). Intestinal infection at onset of mycophenolic acid-associated chronic diarrhea in kidney transplant recipients. Transplant Infectious Disease, 18(5):721-729.

Budde, K; Lehner, F; Sommerer, C; Reinke, P; Arns, W; Eisenberger, U; Wüthrich, R P; Mühlfeld, A; Heller, K; Porstner, M; Veit, J; Paulus, E-M; Witzke, O (2015). Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation, 15(1):119-128.

Wüthrich, R P (2015). Autosomal-dominante polyzystische Nierenerkrankung. Der Nephrologe, 10:376-378.

Wüthrich, R P; Kistler, A D; Rodriguez, Daniel; Kapoor, Sarika; Mei, Changlin (2015). Blood pressure control for polycystic kidney disease. In: Li, Xiaogang. Polycystic kidney disease. Brisbane: Codon Publications, Brisbane, Australia, 95-108.

Wüthrich, R P; Kistler, A D (2015). Blutdruckkontrolle bei Patienten mit polyzystischer Nierenerkrankung. Der Nephrologe, 10:201-206.

Kistler, A D; Wüthrich, R P (2015). Chronische Niereninsuffizienz - welche Therapien können die Progression wirksam verlangsamen. Swiss Medical Forum, 15(11):251-256.

Wüthrich, R P (2015). Genetische Nierenerkrankungen. Der Nephrologe, 10:175.

Stimpfle, D W; Serra, A L; Wüthrich, R P; French, L E; Braun, R P; Hofbauer, G F L (2015). Spectophotometric intracutaneous analysis: an investigation on photodamaged skin of immunocompromised patients. Journal of the European Academy of Dermatology and Venerology, 29(6):1141-1147.

Su, Z; Wang, X; Gao, X; Liu, Y; Pan, C; Hu, H; Beyer, R P; Shi, M; Zhou, J; Zhang, J; Serra, A L; Wüthrich, R P; Mei, C (2014). Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. Journal of Internal Medicine, 276(5):470-485.

Su, Z; Wüthrich, R P; Mei, C (2014). Response to letter from the editor : Complement C3 activation in cyst fluid and urine from autosomal dominant polycystic kidney disease patients. Journal of Internal Medicine, 276(5):541-542.

Cippà, P E; Gabriel, S S; Kraus, A K; Chen, J; Wekerle, T; Guimezanes, A; Wüthrich, R P; Fehr, T (2014). Bcl-2 inhibition to overcome memory cell barriers in transplantation. American Journal of Transplantation, 14(2):333-342.

Denhaerynck, K; Schmid-Mohler, G; Kiss, A; Steiger, J; Wüthrich, R P; Bock, A; De Geest, S (2014). Differences in medication adherence between living and deceased donor kidney transplant patients. International Journal of Organ Transplantation Medicine, 5(1):7-14.

Bühler, M N; Feldmeyer, L; Wüthrich, R P; French, L E; Djamei, V; Serra, A L; Hofbauer, G F L (2013). Die edukative Website Dermaguard zur Präventiontion von Hautkrebs nach Organtransplantation. Praxis, 102(23):1415-1420.

Budde, K; Lehner, F; Sommerer, C; Arns, W; Reinke, P; Eisenberger, U; Wüthrich, R P; Scheidl, S; May, C; Paulus, E-M; Mühlfeld, A; Wolters, H H; Pressmar, K; Stahl, R; Witzke, O (2012). Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. American Journal of Transplantation, 12(6):1528-1540.

Krauer, F; Ahmadli, U; Kollias, S; Bleisch, J; Wüthrich, R P; Serra, A L; Poster, D (2012). Growth of arachnoid cysts in patients with autosomal dominant polycystic kidney disease: serial imaging and clinical relevance. Clinical Kidney Journal, 5(5):405-411.

Gerber, L; Wüthrich, R P; Mohebbi, N (2012). Nierensteine durch Migräne? Praxis, 101(10):665-668.

Pavik, I; Jaeger, P; Ebner, L; Poster, D; Krauer, F; Kistler, A D; Rentsch, K; Andreisek, G; Wagner, C A; Devuyst, O; Wüthrich, R P; Schmid, C; Serra, A L (2012). Soluble Klotho and autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology, 7(2):248-257.

Kistler, A D; Siwy, J; Breunig, F; Jeevaratnam, P; Scherl, A; Mullen, W; Warnock, D G; Wanner, C; Hughes, D A; Mischak, H; Wüthrich, R P; Serra, A L (2011). A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. PLoS ONE, 6(6):e20534.

Raina, S; Honer, M; Krämer, S D; Liu, Y; Wang, X; Segerer, S; Wüthrich, R P; Serra, A L (2011). Anti-VEGF antibody treatment accelerates polycystic kidney disease. American Journal of Physiology. Renal Physiology, 301(4):F773-F783.

Etter, C; Gaspert, A; Regenass, S; Wüthrich, R P; Kistler, T; Kain, R; Cohen, C D (2011). Anti-hLAMP2-antibodies and dual positivity for anti-GBM and MPO-ANCA in a patient with relapsing pulmonary-renal syndrome. BMC Nephrology, 12:26.

Budde, K; Becker, T; Arns, W; Sommerer, C; Reinke, P; Eisenberger, U; Kramer, S; Fischer, W; Gschaidmeier, H; Pietruck, F; ZEUS Study Investigators; Wüthrich, R P (2011). Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, 377(9768):837-847.

Welsh-Bacic, D; Lindenmeyer, M; Cohen, C D; Draganovici, D; Mandelbaum, J; Edenhofer, I; Ziegler, U; Regele, H; Wüthrich, R P; Segerer, S (2011). Expression of the chemokine receptor CCR6 in human renal inflammation. Nephrology, Dialysis, Transplantation, 26(4):1211-1220.

Pavik, I; Jaeger, P; Kistler, A D; Poster, D; Krauer, F; Cavelti-Weder, C; Rentsch, K M; Wüthrich, R P; Serra, A L (2011). Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney International, 79(2):234-240.

Schleich, A; Gerber, L; Wüthrich, R P; Segerer, S (2011). Peri-renal hematoma after intraperitoneal cefazolin treatment for peritonitis. Peritoneal Dialysis International, 31(4):505-507.

Braun, N; Alscher, D M; Fritz, P; Edenhofer, I; Kimmel, M; Gaspert, A; Reimold, F; Bode-Lesniewska, B; Ziegler, U; Biegger, D; Wüthrich, R P; Segerer, S (2011). Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis. Nephrology, Dialysis, Transplantation, 26(3):1033-1041.

Henschkowski, J; Bischoff-Ferrari, H A; Wüthrich, R P; Serra, A L (2011). Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney & Blood Pressure Research, 34(2):97-103.

Hofbauer, G F L; Attard, N R; Harwood, C A; McGregor, J M; Dziunycz, P; Iotzova-Weiss, G; Straub, G; Meyer, R; Kamenisch, Y; Berneburg, M; French, L E; Wüthrich, R P; Karran, P; Serra, A L (2011). Reversal of UVA Skin Photosensitivity and DNA Damage in Kidney Transplant Recipients by Replacing Azathioprine. American Journal of Transplantation, 12(1):218-225.

Copley, J B; Wüthrich, R P (2011). Therapeutic management of post-kidney transplant hyperparathyroidism. Clinical Transplantation, 25(1):24-39.

Lehmann, K; Müller, M K; Schiesser, M; Wildi, S; Fehr, T; Wüthrich, R P; Clavien, P A; Weber, M (2011). Treatment of ureteral complications after kidney transplantation with native ureteropyelostomy reduces the risk of pyelonephritis. Clinical Transplantation, 25(2):201-206.

Serra, A L; Poster, D; Kistler, A D; Krauer, F; Raina, S; Young, J; Rentsch, K M; Spanaus, K S; Senn, O; Kristanto, P; Scheffel, H; Weishaupt, D; Wüthrich, R P (2010). Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. New England Journal of Medicine, 363(9):820-829.

Neusser, M A; Kraus, A K; Regele, H; Cohen, C D; Fehr, T; Kerjaschki, D; Wüthrich, R P; Penfold, M E; Schall, T; Segerer, S (2010). The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection. Kidney International, 77(9):801-808.

Bergamin, B; Senn, O; Corsenca, A; Dutkowski, P; Weber, M; Wüthrich, R P; Segerer, S; Pechula Thut, M (2010). Finding the right position: a three-year, single-center experience with the self-locating catheter. Peritoneal Dialysis International, 30(5):519-523.

Etter, C; Straub, Y; Hersberger, M; Räz, H R; Kistler, T; Kiss, D; Wüthrich, R P; Gloor, H J; Aerne, D; Wahl, P; Klaghofer, R; Ambühl, P M (2010). Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis. European Heart Journal, 31(3):354-359.

Gianella, S; Haeberli, L; Joos, B; Ledergerber, B; Wüthrich, R P; Weber, R; Kuster, H; Hauser, P M; Fehr, T; Mueller, N J (2010). Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transplant Infectious Disease, 12(1):1-10.

Segerer, S; Jedlicka, J; Wüthrich, R P (2010). Atypical chemokine receptors in renal inflammation. Nephron Experimental Nephrology, 115(4):e89-e95.

Serra, A L; Poster, D; Wüthrich, R P (2010). Autosomal-dominante polyzystische Nierenerkrankung : Neue therapeutische Ansätze. Der Nephrologe, 5(5):404-411.

Schorn, R; Höhne, M; Meerbach, A; Bossart, W; Wüthrich, R P; Schreier, E; Müller, N J; Fehr, T (2010). Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clinical Infectious Diseases, 51(3):307-314.

Mueller, N J; Weisser, M; Fehr, T; Wüthrich, R P; Müllhaupt, B; Lehmann, R; Imhof, A; Aubert, J D; Genoni, M; Kunz, R; Weber, M; Steiger, J (2010). Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transplant Infectious Disease, 12(1):54-59.

Wüthrich, R P; Kistler, A D; Serra, A L (2010). Impact of Mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Transplantation Proceedings, 42(9 Supp):S44-S46.

Jedlicka, J; Soleiman, A; Draganovici, D; Mandelbaum, J; Ziegler, U; Regele, H; Wüthrich, R P; Gross, O; Anders, H J; Segerer, S (2010). Interstitial inflammation in Alport syndrome. Human Pathology, 41(4):582-593.

Tian, Y; Chen, J; Gaspert, A; Segerer, S; Clavien, P A; Wüthrich, R P; Fehr, T (2010). Kidney transplantation in mice using left and right kidney grafts. Journal of Surgical Research, 163(2):e91-e97.

Torres, V E; Boletta, A; Chapman, A; Gattone, V; Pei, Y; Qian, Q; Wallace, D P; Weimbs, T; Wüthrich, R P (2010). Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clinical Journal of the American Society of Nephrology, 5(7):1312-1329.

Starke, A; Lindenmeyer, M T; Segerer, S; Neusser, M A; Rüsi, B; Schmid, D M; Cohen, C D; Wüthrich, R P; Fehr, T; Waeckerle-Men, Y (2010). Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney International, 78(1):38-47.

Huber, L C; Wüthrich, R P; Gloor, H J (2010). Wie lautet Ihre Diagnose? Nephrologie. Praxis, 99(17):1011-1013.

Kistler, A D; Mischak, H; Poster, D; Dakna, M; Wüthrich, R P; Serra, A L (2009). Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney International, 76(1):89-96.

Gaspert, A; Lüthi, B; Mueller, N J; Bossart, W; Heim, A; Wüthrich, R P; Fehr, T (2009). Subacute allograft failure with dysuria and hematuria in a kidney transplant recipient. American Journal of Kidney Diseases, 54(1):154-158.

Wüthrich, R P; Segerer, S (2009). Renale Salzregulation: Physiologische Mechanismen und ihre medikamentöse Beeinflussung. Cardiovasc, 5:6-10.

Fellström, B C; Jardine, A G; Schmieder, R E; Holdaas, H; Bannister, K; Beutler, J; Chae, D W; Chevaile, A; Cobbe, S M; Grönhagen-Riska, C; De Lima, J J; Lins, R; Mayer, G; McMahon, A W; Parving, H H; Remuzzi, G; Samuelsson, O; Sonkodi, S; Sci, D; Süleymanlar, G; Tsakiris, D; Tesar, V; Todorov, V; Wiecek, A; Wüthrich, R P; Gottlow, M; Johnsson, E; Zannad, F (2009). Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New England Journal of Medicine, 360(14):1395-1407.

Venzin, R M; Cohen, C D; Maggiorini, M; Wüthrich, R P (2009). Aliskiren-associated acute renal failure with hyperkalemia. Clinical Nephrology, 71(3):326-328.

Grimmelt, A C; Cohen, C D; Fehr, T; Serra, A L; Wüthrich, R P (2009). Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clinical Nephrology, 71(2):125-129.

Kistler, A D; Poster, D; Krauer, F; Weishaupt, D; Raina, S; Senn, O; Binet, I; Spanaus, K; Wüthrich, R P; Serra, A L (2009). Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney International, 75(2):235-241.

Wüthrich, R P; Serra, A L; Kistler, A D (2009). Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney & Blood Pressure Research, 32(5):380-387.

Serra, A L; Wüthrich, R P (2009). Autosomal dominante polyzystische Nierenerkrankung (ADPKD). Pathogenese, Klinik und neue Therapieansätze. Swiss Medical Forum, 2009(47):854-858.

Kistler, A D; Poster, D; Wüthrich, R P; Serra, A L (2009). Hydronephrosis in autosomal dominant polycystic kidney disease. Kidney International, 76(12):1297.

Wüthrich, R P (2009). Immunsuppression bei membranöser Glomerulonephritis - Contra. Deutsche Medizinische Wochenschrift, 134(34-35):1687.

Poster, D; Kistler, A D; Krauer, F; Blumenfeld, J D; Rennert, H; Weishaupt, D; Wüthrich, R P; Serra, A L (2009). Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series. American Journal of Kidney Diseases, 54(3):450-458.

Wüthrich, R P; Serra, A L (2009). Mammalian target of rapamycin and autosomal dominant polycystic kidney disease. Transplantation Proceedings, 41(6 Supp):S18-S20.

Trachsler, J; Glück, Z; Dickenmann, M; Gauthier, T; Brünisholz, M; Martin, P Y; Brunier, M; Wahl, C; Wüthrich, R P (2009). Parameters for successful monthly extended dosing of darbepoetin-a in patients under going hemodialysis. Clinical Nephrology, 71:697-702.

Wu, M; Arcaro, A; Varga, Z; Vogetseder, A; Le Hir, M; Wüthrich, R P; Serra, A L (2009). Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. American Journal of Physiology. Renal Physiology, 297(6):F1597-F1605.

Wüthrich, R P (2009). RAS meets SLE. Nephrology, Dialysis, Transplantation, 24(9):2634-2636.

Serra, A L; Wüthrich, R P (2009). Rapamycin: eine neue Therapieoption bei autosomal dominanter polyzystischer Nierenerkrankung (ADPKD)? Praxis, 98(25):1511-1516.

Fehr, T; Rüsi, B; Fischer, A; Hopfer, H; Wüthrich, R P; Gaspert, A (2009). Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation, 87(12):1837-1841.

Serra, A L; Kistler, A D; Poster, D; Krauer, F; Senn, O; Raina, S; Pavik, I; Rentsch, K; Regeniter, A; Weishaupt, D; Wüthrich, R P (2009). Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 24(11):3334-3342.

Mohebbi, N; Wüthrich, R P (2009). Therapie der nephrogenen Oedeme. Hausarzt Praxis, (9):15-20.

Hofbauer, G F L; Marcollo Pini, A; French, L E; Wüthrich, R P; Serra, A L (2009). mTOR Inhibitoren bremsen gutartige und bösartige vaskuläre Proliferation am Beispiel von Kaposisarkom und Angiofibrom bei tuberöser Sklerose. Dermatologica Helvetica, 21:17-18.

Miele, G; Seeger, H; Marino, D; Eberhard, R; Heikenwalder, M; Stoeck, K; Basagni, M; Knight, R; Green, A; Chianini, F; Wüthrich, R P; Hock, C; Zerr, I; Aguzzi, A (2008). Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS ONE, 3(12):e3870.

Cannata-Andía, J B; Fernández-Martín, J L; Zoccali, C; London, G M; Locatelli, F; Ketteler, M; Ferreira, A; Covic, A; Floege, J; Górriz, J L; Rutkowski, B; Memmos, D E; Verbeelen, D; Tielemans, C; Teplan, V; Bos, W J; Nagy, J; Kramar, R; Goldsmith, D J; Martin, P Y; Wüthrich, R P; Pavlovic, D; Benedik, M (2008). Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). Journal of Nephrology, 21(3):290-298.

Serra, A L; Braun, S C; Starke, A; Savoca, R; Hersberger, M; Russmann, S; Corti, N; Wüthrich, R P (2008). Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. American Journal of Transplantation, 8(4):803-810.

Kunzendorf, U; Krämer, B K; Arns, W; Braun, J; Grossmann, J; Pietruck, F; Schmidt-Gayk, H; Schwarz, A; Ziegler, E; Sperschneider, H; Wüthrich, R P; Nonnast-Daniel, B; Schindler, R; Renders, L (2008). Bone disease after renal transplantation. Nephrology, Dialysis, Transplantation, 23(2):450-458.

Serra, A L; Wüthrich, R P (2008). Use of Cinacalcet to Control Hyperparathyroidism: Treatment with cinacalcet has been shown to be safe and effective in treating primary, secondary, and tertiary hyperparathyroidism. Review of Endocrinology, 2(2):41-45.

Wüthrich, R P (2008). Der organtransplantierte Patient: Kardiovaskuläre Risikofaktoren optimal korrigieren. Cardiovasc, 7(1):1.

Trachsler, J; Gaspert, A; Previsdomini, M; Wüthrich, R P; Fehr, T (2008). Massive uric acid nephrolithiasis with progressive renal failure due to spontaneous tumour lysis syndrome. NDT Plus, 5(1):307-309.

Fehr, T; Wüthrich, R P (2008). Monoklonale Antikörpertherapie bei der Organtransplantation. Swiss Medical Forum, 8(11):204-209.

Wüthrich, R P (2008). Nierenfunktion und nephronsparende Operationstechnik: Nephrologische Sicht. Journal für Urologie und Urogynäkologie, 10:25-27.

Wüthrich, R P (2008). Peritonealdialyse: Für welchen Patienten ist sie geeignet und was ist in der Praxis zu beachten? Medical Journal (TMJ), 5:17-20.

Serra, A L; Wuhrmann, C; Wüthrich, R P (2008). Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. American Journal of Kidney Diseases, 52(6):1151-1157.

Chonchol, M; Wüthrich, R P (2008). Potential future uses of calcimimetics in patients with chronic kidney disease. NDT Plus, 1(Supple):i36-i41.

Wüthrich, R P; Fehr, T (2008). Probleme nach Nierentransplantation: Ein Drittel der Todesfälle geht auf kardiovaskuläre Komplikationen zurück. Cardiovasc, 7:8-12.

Berthier, C C; Wahl, P R; Le Hir, M; Wagner, U; Rehrauer, H; Wüthrich, R P; Serra, A L (2008). Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 23(3):880-889.

Hofbauer, G F L; Marcollo-Pini, A; Corsenca, A; Kistler, A D; French, L E; Wüthrich, R P; Serra, A L (2008). The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. British Journal of Dermatology, 159(2):473-475.

Serra, A L; Wüthrich, R P (2008). Wenn Zysten die Niere zerstöre. Ärztliche Praxis Urologie:18-21.

Waeckerle-Men, Y; Starke, A; Wüthrich, R P (2007). PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrology, Dialysis, Transplantation, 22(6):1527-1536.

Schmidt, T; Wahl, P; Wüthrich, R P; Vogetseder, A; Picard, N; Kaissling, B; Le Hir, M (2007). Immunolocalization of phospho-S6 kinases: a new way to detect mitosis in tissue sections and in cell culture. Histochemistry and Cell Biology, 127(2):123-129.

Serra, A L; Kistler, A D; Poster, D; Struker, M; Wüthrich, R P; Weishaupt, D; Tschirch, F (2007). Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrology, 8:13.

Yakupoglu, H Y; Corsenca, A; Wahl, P; Wüthrich, R P; Ambühl, P M (2007). Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft. Transplantation, 84(9):1151-1157.

Starke, A; Wüthrich, R P; Waeckerle-Men, Y (2007). TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Experimental Nephrology, 107(1):e22-e29.

This list was generated on Tue Jul 25 11:35:35 2017 CEST.